Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
HUGO Series 🌟
HUGO-GT™ (Humanized Genomic Ortholog)
HUGO-Ab™ (Humanized Genomic Ortholog for Antibody)
MouseAtlas Model Library
Flash Sales
Research Models
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
Cell Line Models
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
iPSC Cell Line Product Catalog
AAV Standard Product Catalog
Services
Preclinical Efficacy
Neuroscience
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Models
Human Immune System (HIS) Mouse Model
Metabolic & Cardiovascular Diseases
Anti-Obesity
Autoimmune & Inflammatory
Asthma
Genetically Engineered Animals
Knockout Mice
Transgenic Mice
Knockin Mice
Knockout Rats
Knockin Rats
Transgenic Rats
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Breeding & Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Modalities
Gene Therapy
AI-Powered AAV Discovery
Oligonucleotide Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell Cell Culture
About Us
Corporate Overview
Facility Overview
Animal Health & Welfare
Health Reports
Our Team
Our Partners
Careers
Contact Us
Login
Oncology

Choosing the Right Tumor Model for Preclinical Research

Cyagen Technical Content Team | August 08, 2025
Tumor Mice: Precision Models for Translational Oncology
Our genetically engineered spontaneous tumor mice, developed on immunocompetent backgrounds, closely replicate human tumor biology.
Tumor Mice: Precision Models for Translational Oncology
Contents
01. An Overview of Tumor Models 02. Mouse Tumor Models for Research

Animal models play an important role in the preclinical evaluation of anti-tumor drugs. The establishment of tumor animal models provide a powerful tool for studying the mechanism of tumorigenesis and metastasis, even validating the efficacy of anti-tumor drugs. Rodent models have many advantages in tumor research, such as fast breeding, low cost, and versatile genetic modification. These traits make them an indispensable tool for preclinical therapeutics screening.

An Overview of Tumor Models

It is necessary to establish precise animal models to gain an accurate understanding of tumor pathogenesis, the host-tumor relationship, the process of tumor invasion and metastasis, and the effectiveness of therapeutic measures. Mice share many similarities with humans, such as in genetics, pathology, and biology, so they are ideal animal models for tumor research. Mouse model is a powerful tool to integrating basic and clinical tumor research and has been used in various fields of oncology.

A successful tumor model should meet the following requirements:
  1. Keep the biological characteristics of primary tumor;
  2. The cellular and molecular phenomena associated with tumor growth and metastasis can be studied;
  3. Objective and quantitative indicators;
  4. Reliability, repeatability, effectiveness, and practicality.

Mouse Tumor Models for Research

The use of mouse tumor models makes it possible to achieve the replication of human tumors, which greatly shortens the research timeline, and can help researchers observe the whole process of tumor occurrence and development. It is of great significance for the study of the mechanism of tumor development, prevention, and treatment. With the deepening understanding of tumors and the development of experimental zoology, mouse tumor models have been widely used in various tumor research to achieve significant progress in our understanding of tumor pathologies.

Mouse Tumor Model Types:
① Spontaneous tumor model
② Induced tumor model
③ Transplantation model
④ Genetic engineering model

Spontaneous Tumor Model

Spontaneous tumor model refers to the tumor growth naturally in animal model without any artificial interference. The biggest advantage of the spontaneous tumor models is that the tumor completely occurs under natural conditions, excluding human factors and interventions. The occurrence and development of tumor is like that in humans, reflecting the tumor susceptibility of animals and the accumulation of environmental carcinogens and cancer-promoting substances.

Induced Tumor Model

The induce mouse tumor model is a mouse model which uses chemical carcinogens to induce the occurrence of tumors. At present, chemical carcinogens such as polycyclic aromatic meridians, nitrosamines, and azo dyes are widely applied in inducing tumor models. The selection of animals and carcinogens is particularly important during the establishment of induced mouse tumor model, and the time and degree of carcinogen induction can be controlled by the carcinogen measurement. For example, a tumor can only be induced in some animals, which is related to the sensitivity of animal species and organs, so there is a great difference among species. If the skin cancer is induced by aromatic vertical carcinogens, mouse is the best choice, but it is difficult to induce skin cancer in rats. The carcinogens of nitrosamines can induce esophageal cancer in rats, while only pre gastric cancer can be induced in mice.

Transplantation Model

The transplantation model is formed by transplanting tumor tissue or cells (from animal or human) into the body of the model animal. According to different recipient animals, transplanted tumor models can be divided into normal animal transplanted tumor model and immunodeficient animal transplanted tumor model. Additionally, the source of the tumor tissue determines whether the transplant model is a homograft (same species) or xenograft (different species). Homograft mouse models involves a transplant of tumor tissue into homologous or allogeneic recipient mice, while xenograft mouse model are made by transplanting human tumor tissues into mice to make it grow and develop.

Common xenograft models are outlined below:

Patient-derived Xenograft Model (PDX)

Patient derived xenografts (PDX) model is a tumor model established by transplanting fresh tumor tissue from patients into immunodeficient mice.

Cell Line-derived Xenograft Model (CDX)

Cell line-derived xenograft (CDX) model is a tumor model constructed by transplanting human- or mouse-derived tumor cell lines into immunodeficient mice. As a classical in vivo experimental method, cell line-based tumor models have been widely utilized in oncology research and anti-tumor drug development.

Genetically Engineered Mouse Models

The establishment of genetically engineered and transgenic tumor animal models has become much easier with recent advancements in molecular cloning and microinjection technologies. Studies have found that overexpression, deletion, or mutation of a gene can lead to tumor development in mice. Therefore, we can use genetic engineering methods to introduce oncogenes or knock out tumor suppressor genes to establish genetically modified mouse models of spontaneous or induced tumors, and then carry out corresponding experiments with the model.

Frequently Asked Questions (FAQs)

What is the engraftment efficiency across tumor types?

Cyagen models achieve >80% success for hematologic malignancies and 60–75% for solid tumors (e.g., breast, lung). Variability aligns with human tumor biology rather than model limitations.
Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
Understanding Athymic Nude Mice: Foxn1 Genetics, Immunology and Oncology CDX Applications
Targeted AAV Delivery Strategies for Adipose Tissue: From the Discovery of the Novel BAT Target to In Vivo Validation
Targeting SNCA/TFRC and Overcoming the BBB: The Future of Parkinson’s Disease Therapeutics
Lessons from the Lilly-AC Immune Expansion: Is the "Extracellular Tau Antibody" Era Over?
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Models
HUGO-Ab™ (Humanized Genomic Ortholog for Antibody)HUGO-GT™ (Humanized Genomic Ortholog)MouseAtlas Model LibraryResearch Models
Services
NeuroscienceOphthalmologyOncologyMetabolic & Cardiovascular DiseasesAutoimmune & Inflammatory
About Us
Corporate OverviewFacility OverviewAnimal Health & WelfareHealth ReportsOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research